swisspartners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

swisspartners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$97.5K	Hold	110,000	–	–	0.12%	71
2022 Q3	$173K	Hold	110,000	–	–	0.18%	74
2022 Q2	$228K	Hold	110,000	–	–	0.22%	67
2022 Q1	$256K	Hold	110,000	–	–	0.2%	70
2021 Q4	$518K	Hold	110,000	–	–	0.37%	54
2021 Q3	$839K	Hold	110,000	–	–	0.65%	36
2021 Q2	$1.07M	Hold	110,000	–	–	0.76%	35
2021 Q1	$911K	Buy	+110,000	New	+$1.16M	0.74%	36

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

swisspartners's SRNE Position: Q4 2022 in Review

swisspartners held its Sorrento Therapeutics, Inc. (SRNE) position steady in Q4 2022 at 110,000 shares worth $97.5K. The position accounts for 0.12% of the portfolio, ranked #71.

swisspartners first reported a position in SRNE in Q1 2021 and has held it in 8 quarters since. The position peaked at $1.07M in Q2 2021. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

swisspartners held 110,000 shares of Sorrento Therapeutics, Inc. worth $97.5K as of Q4 2022.
swisspartners left its Sorrento Therapeutics, Inc. share count unchanged in Q4 2022.
Sorrento Therapeutics, Inc. made up 0.12% of swisspartners's portfolio in Q4 2022, its #71 holding.
swisspartners first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and has held it in 8 quarters since.
swisspartners's Sorrento Therapeutics, Inc. position peaked at $1.07M in Q2 2021.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on swisspartners's 13F filing for Q4 2022, filed 14 Feb 2023.